Products

VIDAvision
VIDA Diagnostics
Oncology AI
VIDAvision by VIDA Diagnostics is an FDA-cleared, AI-powered imaging software that provides comprehensive quantitative analysis of chest CT scans for the diagnosis, monitoring, and treatment planning of various lung diseases.

See all 1 product →

About VIDA Diagnostics

VIDA Diagnostics is a clinical imaging intelligence company that leverages AI-powered digital biomarkers to modernize lung and respiratory care, and accelerate the approval and adoption of life-saving therapies. For physicians, VIDA’s solutions provide quantitative data intelligence and impactful visualizations to improve patient outcomes, streamline care coordination, and drive efficiencies in managing patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), asthma, emphysema, lung cancer, and COVID-19. [1, 4, 14, 15, 17, 19, 24, 25, 26, 28, 29]

The company’s AI-powered platform and services are designed to support various aspects of therapeutic research and clinical development. This includes optimizing drug development and discovery through AI-powered insights and rich data repositories, enabling precise quantitative endpoints for clinical trials, and offering services like external control arms and digital twins. [1, 3, 11, 23] VIDA’s software is FDA cleared, CE-marked, Health Canada licensed, TGA registered, and PMDA certified for clinical use in the US, European Economic Area, Canada, Australia, and Japan. [4, 14]

Focus Areas

AI-powered lung imaging analysis clinical trial imaging digital biomarkers respiratory diseases COPD asthma ILD/IPF lung cancer COVID-19 cardiovascular oncology precision medicine

Business Intelligence

Key InvestorsFirst Analysis Corporation, Blue Heron Capital, UnityPoint Health Ventures, Next Level Ventures, Chartline Capital Partners, Rural Vitality Fund, Rittenhouse Ventures, Iowa First Capital Fund, The Angels' Forum, Listwin Ventures, UW Health, Mathers Associates, University of Iowa Research Foundation, Live Oak Bank, BroadOak Capital Partners
PartnershipsThirona, National Jewish Health, Polarean, Riverain Technologies, TeraRecon, Blackford, IBM Watson Health, Nuance Healthcare, RAYUS Radiology
TechnologyVIDA Intelligence Platform, AI-powered system, cloud-native architectures, SaaS-based platforms, deep learning-based segmentation algorithms, ISO 13485:2016 certified quality system, HIPAA compliant
FDA ClearancesMultiple (at least 2 distinct 510(k) clearances) cleared products (estimated)

What Physicians Need to Know

AI-Powered Lung Imaging Analysis
VIDA Diagnostics specializes in AI-powered lung imaging analysis through its LungPrintu00ae solution, offering automated deep learning-based lung and lobe segmentation algorithms. They provide high-quality quantitative CT (QCT) analysis, utilizing over 30 validated imaging biomarkers. Their analysis extends to pulmonary nodules, coronary artery calcification (CAC), and hypodense lung tissue, delivering precise volumetric and density evaluations.
Clinical Trial Imaging & Digital Biomarkers
VIDA accelerates clinical trials with its cloud-based VIDA Intelligence Platform, enabling global clinical trial imaging services. They leverage AI-powered digital biomarker solutions and proprietary imaging biomarkers to provide precise quantitative endpoints, leading to stronger data, smaller cohorts, and shorter timelines. The company operates an ISO-13485 certified core lab and supports over 1,500 certified clinical trial sites globally, managing over 500,000 imaging scans across 30+ active trials.
Comprehensive Respiratory Disease Focus
Their LungPrintu00ae solution is designed to uniquely profile and manage patients with, or at risk of, a wide range of respiratory diseases including COPD (small airway, emphysema), asthma, ILD/IPF (including Data-Driven Texture Analysis (DTA) Fibrosis Score), lung cancer, and COVID-19 related lung damage. The technology aids in early detection and comprehensive assessment of disease probability and progression.
Cardiovascular & Oncology Expansion
Beyond respiratory, VIDA offers digital biomarkers for cardiovascular and oncology trials. Their oncology capabilities include standard tumor response measures like RECIST 1.1 and advanced tumor analysis for solid tumors in the chest or body, imaged with CT, MRI, or PET/CT scanners. They also provide insights into coronary artery calcification (CAC).
Precision Medicine & Personalized Care
VIDA is committed to advancing personalized medicine through precision algorithms and a patient-pathway centric approach. Their solutions empower physicians to develop personalized treatment plans based on anatomical precision and clinical best practices, aiming to improve outcomes and quality of life.
Physician Tip

For physicians, VIDA Diagnostics stands out by offering clinically validated, AI-powered insights that lead to more precise and personalized patient profiles. The LungPrintu00ae solution enables earlier detection of chronic lung diseases, often before debilitating symptoms appear, which can significantly improve patient outcomes and reduce healthcare costs. Physicians benefit from enhanced diagnostic insights through automated radiological metrics, unique time-saving airway visualizations, and richer quantitative CT lung information in radiology reports. The seamless integration of VIDA's technology into existing radiology workflows can lead to substantial efficiency gains, with reported time savings of up to 35% when reading complex chest CT lung stacks. Furthermore, their comprehensive tools support diagnosis, treatment planning, and documentation across a broad spectrum of chest diseases, including complex cases like COVID-19 related lung damage. VIDA's regulatory clearances (FDA, CE-marked, Health Canada, TGA) provide assurance of their solutions' clinical utility and safety.

VIDA's core technology, the VIDA Intelligence Platform, is a cloud-native medical imaging solution that facilitates high-quality, reliable imaging data. It is designed for interoperability, as demonstrated by partnerships with companies like TeraRecon (for distribution through their EnvoyAI platform) and Thirona (for advanced AI-powered lung image analysis). These collaborations unify workflows and provide access to a comprehensive ecosystem of best-in-class AI partners, ensuring standardized biomarker outputs and a secure infrastructure for global trial sites.

Products by VIDA Diagnostics

1 product in the directory

VIDAvision
VIDA Diagnostics
Oncology AI
VIDAvision by VIDA Diagnostics is an FDA-cleared, AI-powered imaging software that provides comprehensive quantitative analysis of chest CT scans for the diagnosis, monitoring, and treatment planning of various lung diseases.

What the Web Says

VIDA Diagnostics appears to be a company with mixed reviews, primarily focusing on employer experiences and, to a lesser extent, product functionality. Employee reviews often highlight a positive work environment and supportive colleagues, but also point to issues with upper management and compensation. Product-wise, there seems to be some confusion in search results, with 'VIDA' also referring to a Volvo diagnostic tool and a musculoskeletal pain reduction service, making it difficult to isolate reviews specifically for VIDA Diagnostics' healthcare IT products. However, some mentions indicate their AI-powered analysis and image analysis services are aimed at transforming pulmonary care.

Overall: Mixed

Strengths

  • Positive work atmosphere and great colleagues.
  • Supportive managers and team.
  • Innovative company driving meaningful change in healthcare with AI.
  • Strong compensation and benefits compared to others in the market (for Vida Health, a related but distinct entity).
  • Open and honest leadership (for Vida Health).
  • Products are easy to use and produce accurate, reproducible results (for VIDAS 3, a bioMu00e9rieux product, not VIDA Diagnostics).

Limitations

  • Issues with upper management and internal politics.
  • Lack of regular raises or evaluation periods.
  • Fast-paced environment with a constant crunch, potentially due to understaffing.
  • Challenges with communication and internal dynamics.
  • Slow response to after-sales service (for VIDAS 3, a bioMu00e9rieux product).
  • Some employees feel undervalued in terms of compensation.

Based on reviews from: Indeed.com, Comparably, Reddit, SelectScience

Last updated: 2026-07-19

Videos

News, demos, and interviews about VIDA Diagnostics.

Loading videos...

Videos load interactively. If none appear, search YouTube for VIDA Diagnostics →

View all on YouTube

Press & Coverage

VIDA Diagnostics
VIDA Partners with Riverain Technologies to Extend Best-of-Breed AI Imaging for Life Sciences
VIDA Diagnostics announced a strategic partnership with Riverain Technologies to integrate Riverain's ClearReadu2122 CT cardiothoracic AI imaging analysis suite into the VIDA Intelligence Platform, aiming to provide pharmaceutical science teams with comprehensive precision imaging biomarker services. This collaboration, announced at RSNA 2025, will enhance the understanding of complex diseases like COPD, cardiovascular disease, and lung cancer.
2025-11
VIDA Diagnostics
VIDA Partners with Thirona to Expand Respiratory Clinical Trial Imaging Capabilities
VIDA Diagnostics announced a strategic partnership with Thirona at the European Respiratory Society (ERS) meeting in Amsterdam, allowing trial sponsors to access Thirona's advanced AI-powered quantitative analyses through VIDA's trial imaging services. This partnership expands VIDA's respiratory services and provides customers with access to innovative AI-powered lung analyses.
2025-09
NS Medical Devices
Polarean, VIDA to deploy xenon 129 MRI platform in clinical and research settings
Polarean has partnered with VIDA Diagnostics to expand the capabilities of Polarean's xenon 129 MRI platform, aiming to integrate xenon 129 MRI workflow into clinical care and develop automated image processing. This collaboration will also establish a clinical trial network for pharma-sponsored drug and device development using standardized xenon 129 MR image acquisition and data-sharing methods.
2026-02
Imaging Technology News
VIDA Launches VIDA Intelligence Portal 2.0 to Accelerate Onboarding of Clinical Trial Sites
VIDA Diagnostics announced the availability of VIDA Intelligence Portal 2.0, a significant upgrade to its cloud-native, AI-enabled Intelligence platform designed to optimize staff training, image data collection, and data quality in clinical trial imaging operations. The new digital onboarding features simplify the enrollment process for trial sites, and the global network of sites equipped with the portal has expanded to over 1,000.
2022-12
AuntMinnie
Vida receives FDA clearance for AI lung software
Vida Diagnostics received 510(k) clearance from the FDA to add automated segmentation to its AI-powered lung analysis software, LungPrint, enabling improved lung imaging analysis and more comprehensive assessments of disease likelihood and progression. This clearance allows for the use of deep-learning algorithms for lung and lobe segmentation, aiding clinicians in developing personalized treatment plans.
2020-09
Respiratory Therapy
FDA Clears Vida Diagnostics Additions to Lung Imaging Solution
Vida Diagnostics Inc. received 510(k) clearance from the FDA for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. These additions improve lung imaging analysis and enable more comprehensive assessments of disease probability and progression, empowering physicians to develop personalized treatment plans.
2020-09
Mercom Capital Group
VIDA Diagnostics Raises $11 Million in Series C Funding
VIDA Diagnostics, an AI-powered lung imaging analysis company, raised $11 million in Series C funding led by First Analysis Corporation, with participation from Blue Heron Capital, UnityPoint Health Ventures, and existing investors. The funds will be used to accelerate the commercialization of its LungPrintu00ae solution suite and expand its clinical portfolio to address market deficits in early assessment, monitoring, and treatment of lung disease.
2020-03
PR Newswire
VIDA Announces Series C Financing To Accelerate Access To AI-Powered Lung Imaging Analysis
VIDA Diagnostics, Inc. announced an $11 million initial close of its Series C financing, led by First Analysis Corporation. The funding will be used to accelerate the commercialization of its LungPrintu00ae solution suite and expand its clinical portfolio to improve the early assessment, monitoring, and treatment of lung disease.
2020-03

Frequently Asked Questions

VIDA Diagnostics offers the LungPrintu00ae solution, an AI-powered suite for profiling and managing patients with respiratory diseases, available for both clinical use and clinical trials. Their VIDA Intelligence Platform provides advanced imaging biomarkers and streamlines imaging data management for research and drug development across various lung conditions.
VIDA Diagnostics supports clinical trials through its VIDA Intelligence Platform, which manages high-quality imaging data and offers a wide array of AI-powered digital biomarkers. These biomarkers span major respiratory diseases like COPD, asthma, ILD/IPF, lung cancer, and COVID-19, and also extend to cardiovascular and oncology trials, generating thousands of metrics from a single scan.
VIDA Diagnostics' software is FDA cleared, CE-marked, Health Canada licensed, and TGA registered for clinical use in the US, European Economic Area, Canada, and Australia. The company is HIPAA compliant, and its quality system is certified to the ISO 13485:2016 standard, also complying with FDA Part 11 requirements.
VIDA Diagnostics provides customer support through its Customer Success team, accessible via phone and email, and offers eLearning and certification through its Intelligence Portal for trial sites. They have strategic partnerships with companies like Thirona, TeraRecon, Riverain Technologies, and Polarean to expand their AI-powered analysis and distribution, as well as collaborations with healthcare systems like OSF HealthCare and RAYUS Radiology.
Founded in 2005, VIDA Diagnostics is recognized as a leader in clinical imaging intelligence, having secured significant funding rounds, including a $13M Series C in 2020. Their VIDA Intelligence Platform is utilized by over 1,500 sites globally, demonstrating a strong and expanding market presence in transforming lung care through AI-powered insights.
VIDA Diagnostics' LungPrintu00ae solution and AI-powered digital biomarkers provide precise, personalized profiles of pulmonary health, aiding in the diagnosis and treatment planning for a range of lung diseases. This includes conditions such as COPD, asthma, ILD/IPF, and lung cancer, enabling clinicians to develop tailored treatment plans based on quantitative imaging analysis.
Yes, while VIDA Diagnostics has a strong foundation in respiratory diseases, their AI-powered imaging biomarkers and clinical trial services have expanded to include digital biomarkers for cardiovascular and oncology trials. This allows for a broader application of their quantitative imaging intelligence across multiple therapeutic areas.

Related Companies

Intelligent Voice AI (IVAI) is an agentic AI platform that deploys AI voice agents specifically designed for healthcare, insurance, legal, and home services businesses. For physicians and medical practices, IVAI’s Evolve AI Agents act as an AI workforce, not just an answering service, handling a comprehensive range of administrative and operational tasks. These agents can […]

Dext, formerly known as Receipt Bank, is a company that specializes in bookkeeping automation, leveraging data, technology, and applied AI to enhance productivity and efficiency for businesses, accountants, and bookkeepers. [3, 16] Their platform is designed to streamline financial document management and automate bookkeeping tasks, aiming to simplify the accounting process and enable more informed […]

Cortex (https://www.cortex.app) is an AI-powered internal developer portal designed to enhance engineering excellence and streamline software development workflows. For physicians, this translates to a platform that can indirectly improve healthcare technology by enabling engineering teams to build more reliable, secure, and efficient software. The platform helps in cataloging, scoring, and assigning actions to improve service […]

Nino is an AI-powered financial planning and tax service that aims to provide comprehensive financial guidance. For physicians, Nino’s AI software can help manage income, student loans, and plan career transitions, such as moving from training to practice or considering practice ownership. The platform allows physicians to view loans, income, and savings in one place, […]

Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]

SamaCare is a healthcare AI company that provides a cloud-based workflow intelligence platform designed to streamline the prior authorization process for specialty medications. The company’s platform aims to reduce the administrative burden on medical practices, improve approval rates, and add predictability to patient care. By digitizing the often manual and paper-heavy prior authorization process, SamaCare […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.